Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Financing Activities (2020 - 2023)

Historic Cash from Financing Activities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $248000.0.

  • Cullinan Therapeutics' Cash from Financing Activities rose 10075.35% to $248000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $40.8 million, marking a year-over-year increase of 25713.96%. This contributed to the annual value of $266.2 million for FY2024, which is 55320.61% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Cash from Financing Activities stood at $248000.0 for Q4 2023, which was up 10075.35% from $112000.0 recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Cash from Financing Activities peaked at $264.6 million during Q1 2021, and registered a low of -$32.9 million during Q4 2022.
  • Over the past 4 years, Cullinan Therapeutics' median Cash from Financing Activities value was $1.8 million (recorded in 2023), while the average stood at $28.2 million.
  • In the last 5 years, Cullinan Therapeutics' Cash from Financing Activities tumbled by 131806.07% in 2022 and then surged by 181763.54% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Cash from Financing Activities (Quarter) stood at $124.9 million in 2020, then tumbled by 97.84% to $2.7 million in 2021, then crashed by 1318.06% to -$32.9 million in 2022, then soared by 100.75% to $248000.0 in 2023.
  • Its Cash from Financing Activities was $248000.0 in Q4 2023, compared to $112000.0 in Q3 2023 and $38.6 million in Q2 2023.